Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited announced that the U.S. FDA has classified its Pithampur Unit-2 manufacturing facility inspection as ‘Official Action Indicated’ (OAI) following an earlier inspection that resulted in a Form-483 with four observations. The company is actively working with the FDA to address the compliance issues and ensure adherence to CGMP standards across all its facilities. This development may have implications for Lupin’s operations and its standing in the pharmaceutical industry, particularly in the U.S. market.
More about Lupin Limited
Lupin Limited is a pharmaceutical company based in Mumbai, India, primarily engaged in the development, manufacture, and sale of a wide range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company focuses on the global pharmaceutical market, with a significant presence in the United States and other international markets.
Average Trading Volume: 20,290
Technical Sentiment Signal: Buy
Current Market Cap: 905.2B INR
For an in-depth examination of LUPIN stock, go to TipRanks’ Overview page.